INCYTE CORP
INCYNasdaq · SIC 8731
$117.25
↑ +0.5%Jul 17 close · end-of-day
Price
1Y↑ +69.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$24.3B
Enterprise Value
$20.8B
P/E
16.6
P/S
4.5
P/B
4.3
EV/EBITDA
12.2
PEG
0.3
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$5.4B
Net Income (TTM)
$1.4B
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
30.0%
Net Margin
26.7%
ROE
25.5%
ROIC
60.1%
Debt / Equity
—
Net Cash
$3.5B
Return 1Y
+70.1%
Company profile
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD) It also develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
- CEO
- Herve Hoppenot
- Sector
- Services
- Industry
- Business Services
- Employees
- 2,320
- Headquarters
- Delaware
- Website
- incyte.com
Management & directors
- Cagnoni Pablo JPresident, Global Head of R&D
- Issa Mohamed KhairieEVP, Head of U.S. Commercial
- Mayes Patrick AEVP & Chief Scientific Officer
- Stein Steven HCMO & Head of Late-Stage Dev.
- Tray ThomasPrincipal Accounting Officer
- Meury WilliamChief Executive Officer
- Upadhyay SuketuEVP & Chief Financial Officer
- Trotta MatteoEVP, GM, Dermatology US
- Heeson LeeEVP, Head of Incyte Intl
- Morrissey Michael JamesEVP, Head of Tech. Operations
- Hoffman Richard A.EVP & General Counsel
- Denton Sheila A.EVP & General Counsel
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-07-28
INCY Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.3B↑ +20.9%
Diluted EPS$1.47↑ +83.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.7B | $3.0B | $3.4B | $3.7B | $4.2B | $5.1B |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$263.7M | $585.8M | $579.4M | $620.5M | $61.4M | $1.5B |
| Net income | -$295.7M | $948.6M | $340.7M | $597.6M | $32.6M | $1.3B |
| Diluted EPS | -$1.36 | $4.27 | $1.52 | $2.65 | $0.15 | $6.41 |
| Operating cash flow | -$124.6M | $749.5M | $969.9M | $496.5M | $335.3M | $1.4B |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -9.9% | 19.6% | 17.1% | 16.8% | 1.4% | 29.5% |
| Net margin | -11.1% | 31.8% | 10.0% | 16.2% | 0.8% | 25.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $1.1B | $1.2B | $1.1B | $1.2B | $1.4B | $1.5B | $1.3B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$478.1M | $146.1M | $301.5M | $205.2M | $530.3M | $443.5M | $335.9M | $301.1M |
| Net income | -$444.6M | $106.5M | $201.2M | $158.2M | $405.0M | $424.2M | $299.3M | $303.3M |
| Diluted EPS | -$2.04 | $0.54 | $0.90 | $0.80 | $2.04 | $2.11 | $1.46 | $1.47 |
| Operating cash flow | -$575.6M | $310.9M | $381.2M | $266.1M | $44.7M | $559.4M | $543.3M | $369.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -45.8% | 12.8% | 25.6% | 19.5% | 43.6% | 32.5% | 22.3% | 23.7% |
| Net margin | -42.6% | 9.4% | 17.1% | 15.0% | 33.3% | 31.1% | 19.9% | 23.8% |
Company news
Jul 20, 2026
- 8h agoHalozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Developmentinvestorshub.advfn.com
- 11h agoHalozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technologyfinance.yahoo.com
Jul 16, 2026
Jul 13, 2026
- 7d agoSector Update: Healthcare Stocks Advance Late Afternoonfinance.yahoo.com
- 7d agoOwn Regeneron For Biotech Growth? Incyte Is Making Its Case.trefis.com
- 7d agoIncyte (INCY) Could Be 8% Overvalued As Latarcibart Moves Into Phase 3finance.yahoo.com
- 7d agoHow Investors May Respond To Incyte (INCY) Latarcibart Data In Von Willebrand Disease Prophylaxisfinance.yahoo.com
- 7d agoIncyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorderfinance.yahoo.com
- 7d agoUnpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocksfinance.yahoo.com
- 7d agoIncyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Typesfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Stein Steven H· CMO & Head of Late-Stage Dev. | Sale | 28,237 | $113.05 | $3.2M | filing |
| 2026-07-15 | CAGNONI PABLO J· President, Global Head of R&D | Tax withholding | 4,950 | $115.09 | $569,695.50 | filing |
| 2026-07-15 | Stein Steven H· CMO & Head of Late-Stage Dev. | Tax withholding | 3,088 | $115.09 | $355,397.92 | filing |
| 2026-07-15 | Mayes Patrick A· EVP & Chief Scientific Officer | Tax withholding | 1,512 | $115.09 | $174,016.08 | filing |
| 2026-07-15 | Issa Mohamed Khairie· EVP, Head of U.S. Commercial | Tax withholding | 1,099 | $115.09 | $126,483.91 | filing |
| 2026-07-15 | Tray Thomas· Principal Accounting Officer | Tax withholding | 1,098 | $115.09 | $126,368.82 | filing |
| 2026-07-14 | Stein Steven H· CMO & Head of Late-Stage Dev. | Tax withholding | 21,830 | $114.88 | $2.5M | filing |
| 2026-07-14 | CAGNONI PABLO J· President, Global Head of R&D | Tax withholding | 17,969 | $114.88 | $2.1M | filing |
| 2026-07-14 | Tray Thomas· Principal Accounting Officer | Tax withholding | 692 | $114.88 | $79,496.96 | filing |
| 2026-07-14 | Mayes Patrick A· EVP & Chief Scientific Officer | Tax withholding | 437 | $114.88 | $50,202.56 | filing |
| 2026-07-02 | Meury William· Chief Executive Officer | Tax withholding | 4,779 | $116.86 | $558,473.94 | filing |
| 2026-07-02 | Stein Steven H· CMO & Head of Late-Stage Dev. | Tax withholding | 2,177 | $116.86 | $254,404.22 | filing |
| 2026-07-02 | Tray Thomas· Principal Accounting Officer | Tax withholding | 477 | $116.86 | $55,742.22 | filing |
| 2026-07-02 | Mayes Patrick A· EVP & Chief Scientific Officer | Tax withholding | 350 | $116.86 | $40,901.00 | filing |
| 2026-06-30 | HARRIGAN EDMUND | Award | 255 | $113.36 | $28,906.80 | filing |
| 2026-06-30 | Clancy Paul J | Award | 252 | $113.36 | $28,566.72 | filing |
| 2026-06-30 | 667, L.P. | Award | 400 | $0.00 | $0.00 | filing |
| 2026-06-30 | BAKER BROS. ADVISORS LP | Award | 400 | $0.00 | $0.00 | filing |
| 2026-06-30 | Baker Bros. Advisors (GP) LLC | Award | 400 | $0.00 | $0.00 | filing |
| 2026-06-30 | Baker Brothers Life Sciences LP | Award | 400 | $0.00 | $0.00 | filing |
| 2026-06-30 | BAKER FELIX | Award | 400 | $0.00 | $0.00 | filing |
| 2026-06-30 | BAKER JULIAN | Award | 400 | $0.00 | $0.00 | filing |
| 2026-06-08 | BRAWLEY OTIS W | Award | 1,642 | $0.00 | $0.00 | filing |
| 2026-06-08 | BAKER BROS. ADVISORS LP | Award | 1,642 | $0.00 | $0.00 | filing |
| 2026-06-08 | BAKER BROS. ADVISORS LP | Award | 1,642 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.